Recent Advances in the Treatment of Alopecia Areata

The expert panel highlights the psychosocial burden of alopecia areata on patients and discusses the current treatment paradigm.

Drs. Raj Chovatiya, George Han, and Brett King discuss the use of baricitinib for the treatment of moderate to severe alopecia areata.

The expert panel discusses the secondary analysis from the phase 3 BRAVE clinical trials of baricitinib in alopecia areata.

Dr. Brett King shares novel mechanisms of action under research for the treatment of alopecia areata in different age groups.

Expert dermatologists discuss the importance of continued education for physicians treating patients with alopecia areata.

Panelists discuss the efficacy and safety data for ritlecitinib and deuruxolitinib in treating alopecia areata, highlighting that ritlecitinib achieved SALT scores of ≤20 in 23% of patients at week 24 compared to 1.6% in the placebo group, while deuruxolitinib showed SALT scores of ≤20 in 42.5% (8mg BID ) and 56.8% (12mg BID) of patients, with treatment-emergent adverse events primarily being mild to moderate, including upper respiratory tract infections and headaches for ritlecitinib, and headache and acne for deuruxolitinib.

Panelists discuss their clinical experiences with Janus kinase (JAK) inhibitors for treating alopecia, noting observed differences in outcomes and tolerability among various systemic JAK inhibitors, while highlighting the advantages of these therapies over traditional local and systemic treatment options.